




Plecanatide

Revised: November 16, 2020.

CASRN: 467426-54-6



Drug Levels and Effects

Summary of Use during Lactation

Plecanatide is not absorbed from the gastrointestinal tract and the drug and its active metabolite are not measurable in milk following administration of recommended doses to nursing mothers. Plecanatide is not expected to cause any adverse effects in breastfed infants. No special precautions are required.

Drug Levels

Maternal Levels. Plecanatide 3 mg was administered orally once daily for 2 weeks to 7 mothers who had been nursing for at least 4 weeks. Plecanatide and its active metabolite were not measurable (detection limit not specified) in breastmilk samples collected before a dose or at 2, 6, or 12 hours after a dose.[1,2]

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Alternate Drugs to Consider

(Irritable Bowel Syndrome) Linaclotide, Lubiprostone, Prucalopride, Psyllium, Tenapanor

Substance Identification

Substance Name

Plecanatide

CAS Registry Number

467426-54-6

Drug Class

Breast Feeding

Lactation

Gastrointestinal Agents

Peptides

Guanylyl Cyclase C Agonists

Laxatives